Clinical Trials Logo

Amyloidosis clinical trials

View clinical trials related to Amyloidosis.

Filter by:

NCT ID: NCT06328075 Recruiting - Clinical trials for Amyloid Cardiomyopathy

Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis

AI-ATTR-ECHO
Start date: January 1, 2022
Phase:
Study type: Observational

The goal of this study is to develop an algorithm using artificial intelligence (AI) to assist identification of potential ATTR-CM cases using routine transthoracic echocardiography. The main questions it aims to answer are: - is the algorithm able to diagnose ATTR-CM - is the algorithm able to diagnose different types of ATTR-CM (ATTRv, ATTRwt) This is a non interventional study. Participant' echocardiographies will be, after deidentification, used to train, valid and test the algorithm.

NCT ID: NCT06321523 Not yet recruiting - Clinical trials for Transthyretin Amyloid Cardiomyopathy

A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Start date: March 18, 2024
Phase:
Study type: Observational

The purpose of this clinical trial is to learn about the effects of the study medicine (called Tafamidis 61milligrams (mg)) for the potential treatment of Transthyretin amyloid cardiomyopathy (ATTR-CM). This study is seeking participants who were prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once. We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective.

NCT ID: NCT06318260 Recruiting - Clinical trials for ATTR Amyloidosis Wild Type

Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)

DobATTR
Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to test the effects of the inotropic drug named dobutamine, in patients with wild-type Transthyretin Amyoid Cardiomyopathy (ATTRwt). The main questions it aims to answer are: - What are the effects of increasing dosages of dobutamine infusion on cardiac output and filling pressures in patients with symptomatic ATTRwt. - Safety of dobutamine infusion in this patient population. Participants will be given increasing dosages of dobutamine infusion, and its effect on cardiac output and filling pressures will be assessed non-invasively by echocardiography, and invasively by right heart catheterization, simultaneously.

NCT ID: NCT06292780 Not yet recruiting - Clinical trials for Relapsed/Refractory Systemic Light Chain Amyloidosis

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

LINKER-AL2
Start date: April 29, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again. The study consists of 2 phases (Phase 1 and Phase 2): - In Phase 1, linvoseltamab will be given to a small number of participants to study the side effects of the study drug and to determine the recommended doses of the study drug to be given to participants in Phase 2. - In Phase 2, linvoseltamab will be given to more participants to continue to assess the side effects of the study drug and to evaluate the ability of linvoseltamab to treat AL amyloidosis. The study is looking at several other research questions, including: - How many participants treated with linvoseltamab have improvement in the abnormal proteins that cause organ problems and for how long - How many participants treated with linvoseltamab have improvement in the heart or kidney and for how long - What the right dosing regimen is for linvoseltamab - What side effects may happen from taking linvoseltamab - How much linvoseltamab is in your blood at different times - Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects)

NCT ID: NCT06291805 Recruiting - Quality of Life Clinical Trials

Phenotyping and Characterization of wtATTR-CM (TRACE 1)

Start date: February 20, 2024
Phase:
Study type: Observational

Descriptive cross-sectional study on 100 consecutive ATTRwt-CM patients reflecting all NAC stages aiming primarily to investigate ATTRwt-CM patient's quality of life (QoL) measures and their relation to ATTRwt-CM severity. Secondarily aiming to investigate the possibility to measure misTTR and fragTTR in plasma and urine and to detect fragTTR in endomyocardial biopsies from ATTRwt-CM patients. To investigate whether misTTR and fragTTR levels are correlated with ATTRwt-CM severity.

NCT ID: NCT06261216 Recruiting - Clinical trials for Amyloid Cardiomyopathy

Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy

Start date: February 2024
Phase:
Study type: Observational

The aim of this study is to investigate the association between increased lifetime physical activity and the development of wild-type transthyretin amyloid cardiomyopathy.

NCT ID: NCT06260709 Recruiting - Clinical trials for Transthyretin Amyloid Cardiomyopathy (ATTR CM)

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Start date: February 20, 2024
Phase: Phase 2
Study type: Interventional

This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis". Only participants who have completed that study will be invited for this new study. Participants will get NNC6019-0001, regardless of whether they got placebo or NNC6019-0001 in the first study. The study will last for up to 157 weeks (36 months/3 years).

NCT ID: NCT06257485 Recruiting - Clinical trials for Transthyretin Amyloid Cardiomyopathy

Bronx Transthyretin Amyloid Cardiomyopathy Database

Start date: September 23, 2023
Phase:
Study type: Observational

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.

NCT ID: NCT06251778 Recruiting - Amyloidosis Clinical Trials

NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis

NOTE-ATTR
Start date: January 26, 2024
Phase:
Study type: Observational

All ATTRwt patients on tafamidis 61 mg treatment will be clinically evaluated before treatment initiation and subsequently every six months for the eligibility to continue tafamidis treatment, according to Italian Medicines Agency regulations. C onsidering the significant risk of developing heart rhythm disturbances due to cardiac amyloidosis, especially in transthyretin form (ATTRwt), in routine clinical practice a stricter heart rhythm monitoring is recommended in ATTRwt patients. Moreover, particular attention is usually paid for those who present atrio-ventricular and/or intraventricular block at the baseline electrocardiogram. Data about rhythm disturbances and diuretic dose need will be collected during the planned physical examination every six months and the Holter ECG monitoring requested by the physician at the end of every planned clinical evaluation.

NCT ID: NCT06249243 Not yet recruiting - Clinical trials for Urinary System Disorders in IBD Patients

Affection of Renal and Urinary System in IBD Patients

Start date: February 20, 2024
Phase:
Study type: Observational

Detection and classification of different renal and urinary affection in patients with IBD that attended to Assist University Hospitals